Abstract: Stabilized trimers of a clade A strain and a clade C strain of HIV-1 are provided. Broadly neutralizing antisera against HIV-1, methods of making broadly neutralizing antisera against HIV-1, broadly neutralizing vaccines against HIV-1, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided.

Abstract: Apparatus and methods for producing narrow-band radiation in the green region of the visible spectrum are described. The narrow-band radiation may be used to aid subjects experiencing photophobia. In some cases, subjects may experience a reduction in pain (e.g., migraine photophobia) when using the narrow-band radiation.

Abstract: The invention relates to immunogenic compositions and vaccines containing a ZIKV protein or a polynucleotide encoding a Zika virus (ZIKV) protein and uses thereof. The invention also provides methods of treating and/or preventing a ZiKV infection by administering an immunogenic composition or vaccine of the invention to a subject (e.g., a human).

Abstract: The invention provides, inter alia, fatty acyl hydroxy fatty acid (FAHFA; a novel class of estolide-related molecules) and diagnostic and treatment methods for a variety of disorders—including diabetes-related disorders, Metabolic Syndrome, polycystic ovarian syndrome, cancer, and inflammatory disorders—using them; as well as methods of screening for additional compounds that are useful in treating these disorders and/or that modulate FAHFA levels, FAHFA-mediated signaling, and FAHFA-mediated biological effects.

Abstract: The present disclosure relates to the identification of genes and gene combinations that are correlated with patients having or being predisposed to developing pancreatic ductal adenocarcinoma (PDAC). In some instances, methods herein utilize panels of 5 or 10 genes to accurately diagnose PDAC, determine the likelihood of developing PDAC, or determine the severity/stages of PDAC. These panels may be used in a molecular diagnostic test.

Abstract: The present invention relates to antibodies specific for a particular epitope on CD40 and antibodies that bind CD40 and have particular functional characteristics. The present invention also relates to fragments of these antibodies, uses of the antibodies for reduction or treatment of transplant rejection and graft-versus-host disease, and methods for making the antibodies.

Abstract: The invention features all-trans retinoic acid (ATRA)-related compounds capable of associating with Pin1 and methods of treating a proliferative disorder characterized by elevated Pin1 marker levels, Pin1 degradation, and/or reduced Pin1 Ser71 phosphorylation in a subject by administering an ATRA-related compound. The invention also features methods of treating proliferative disorders, autoimmune diseases, and addiction conditions (e.g., diseases, disorders, and conditions characterized by elevated Pin1 marker levels) by administering an ATRA-related compound in combination with another therapeutic compound.

Abstract: Methods for treating cancer, e.g., in conjunction with anti-cancer therapy, like immunotherapy, and for identifying candidate therapeutic agents, by targeting ICAM4. While MDSCs in mice have been extensively characterized, their human counterparts are not well defined, and cell markers present in mice are not always usable in humans. MDSCs have been described as a heterogenous population of myeloid derived cells with immune suppressive capacity (5, 9, 40, 41). Recent renewed interest in the role of MDSC accumulation in human tumors has resulted in the increased need to define these cells better in order to target them for therapeutic intervention.

Abstract: The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the compounds of Formula (I) or (II), or compositions thereof, for treating or preventing a wide range of diseases (e.g., proliferative diseases (e.g., cancers, benign neoplasms, angiogenesis, inflammatory diseases, autoimmune diseases) and metabolic diseases (e.g., diabetes (e.g., type 2 diabetes, gestational diabetes)) in a subject. Treatment of a subject with a disease using a compound of Formula (I) or (II), or compositions thereof, may downregulate the expression and/or inhibit the activity of a kinase (e.g., a tyrosine kinase, such as a Tec kinase, in particular, bone marrow on X chromosome kinase (BMX)), and therefore, suppress tyrosine kinase singling in the subject.

Abstract: A system and method for controlling a magnetic resonance imaging (MRI) system to acquire images of a subject having inconsistencies in a cardiac cycle of the subject. The process includes receiving an identification of a predetermined point in a cardiac cycle of the subject and, thereupon, performing a saturation module configured to dephase magnetization within a region of interest (ROI) from before the predetermined point. The process also includes performing an inversion module configured to invert spins within the ROI and acquiring medical imaging data from the subject. A delay is inserted between the performance of the saturation module and the performance of the inversion module, wherein a duration of the delay is configured, with the saturation module, to control evidence in the medical imaging data of inconsistencies in the cardiac cycle of the subject by controlling a magnetization history of tissue in the ROI.

Abstract: Methods for inducing an immune response against Human Immunodeficiency Virus (HIV) in HIV-infected subjects undergoing antiretroviral therapy (ART) are described. The methods include administering an adenovirus vector primer vaccine and a modified vaccinia virus (MVA) vector booster vaccine encoding mosaic HIV antigens.

Abstract: A method and system for determining a patient's risk of ventricular tachycardia are disclosed. The method includes receiving ECG signals from a patient and filtering the collected ECG signals to generate filtered ECG signals. The method further includes identifying a heart vector from the filtered ECG signals, and measuring a velocity of the heart vector movement. A change in curvature of the identified heart vector movement is quantified and a risk of ventricular tachycardia is determined based at least on the measured velocity and the quantified change in curvature of the identified heart vector movement.

Abstract: An MRI method includes: performing a first data acquisition block of a pulse sequence to acquire a first MR data from a plurality of slices of a subject during a period of fully recovered longitudinal magnetization within the plurality of slices disposed at different locations in the subject; performing a second data acquisition block of the pulse sequence including a magnetization preparation module followed by a recovery period and an imaging sequence executed during the recovery period, to acquire a second MR data from the plurality of slices during the recovery period; and generating a T1 map of the subject based on the first MR data and the second MR data, of the plurality of slices.

Abstract: This disclosure relates to the compounds of formula (I): [INSERT FORMULA], in which A and R1-R12 are defined in the Specification. The compounds of formula (I) have therapeutic effects, such as treating cancers.

Abstract: The invention features methods of treating a proliferative disorder characterized by elevated Pin1 marker levels and/or reduced Pin1 Ser71 phosphorylation in a subject by administering a retinoic acid compound. Additionally, the invention features methods of treating proliferative disorders (e.g., proliferative disorders characterized by elevated Pin1 marker levels) by administering a retinoic acid compound in combination with another anti-proliferative compound. Finally, the invention also features methods including high-throughput screens for discovering and validating Pin1 inhibitors.

Abstract: The present invention features methods and compositions for the generation of conformation-specific antibodies.

Abstract: The present invention relates to compositions for and methods of optically imaging tissues or cells using imaging agents having desirable in vivo properties that result in improved signal-to-background ratio.

Abstract: Compositions, vaccines and methods for inducing protective immunity against Human Immunodeficiency Virus (HIV) infection are described. Heterologous vaccine combinations of one or more viral expression vectors and an isolated antigenic polypeptide induced strong protective immunity against infections by one or multiple clades of HIV.

Abstract: Stabilized trimers of a clade A strain and a clade C strain of HIV-1 are provided. Broadly neutralizing antisera against HIV-1, methods of making broadly neutralizing antisera against HIV-1, broadly neutralizing vaccines against HIV-1, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided.

Abstract: Embodiments of the present invention relate to biomarkers, including signatures containing a plurality of such biomarkers, which are predictive of responsiveness to therapy of gastrointestinal inflammatory disorders such as inflammatory bowel diseases (IBD), e.g., ulcerative colitis and Crohn's disease, with TNF? inhibitors or JAK-STAT inhibitors, such as anti-TNF? antibodies and JAK inhibitors. Further embodiments relate to the use of such biomarkers and/or signatures in determining the responsiveness of a patient with IBD to therapy with TNF? inhibitors or JAK inhibitors, such as anti-TNF? antibodies or small molecule JAK inhibitors. Additional embodiments relate to methods of treating gastrointestinal inflammatory disorders in patients, based on detection of one or more biomarkers.